Q-omics provides the consensus-scored OR2L13 profile across patient tissues and cancer cell-line models. OR2L13 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, OR2L13 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, OR2L13 RNA expression shows 10,649 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, COAD, and GBM as cancer lineages where OR2L13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2L13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2L13 survival associations across molecular data types. OR2L13 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2L13 RNA expression–survival associations across cancer types. High OR2L13 expression shows unfavorable associations in LUSC and CESC, but favorable associations in BRCA, UVM, ESCA and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for OR2L13 RNA expression.
This table summarizes OR2L13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR2L13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2L13 shows lower tumor expression in COAD, BRCA, UCEC, KICH and READ and higher tumor expression in HNSC. The COAD box plot shows higher OR2L13 RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p < 0.001).
This table shows molecular features associated with OR2L13 in patient tissues and cancer cell lines. In patient samples, OR2L13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2L13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
